Filing Flows

Filing Flows › Companies › Castle Biosciences › Cash flow

Castle Biosciences cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$12.2M in Q3 2026 · $4.0M over twelve months

Operating cash flow$19.7M
Capital spending−$7.5M
Free cash flow+$12.2M
Cash conversion cycle41 days

Analysis

In Q3 2026, Castle Biosciences generated $19.7M of operating cash flow and spent $7.5M on capital projects, leaving free cash flow of $12.2M. That is $4.5M more than in Q3 2025 ($7.8M).

Over the twelve months to Sep 30, 2026, operating cash flow was $39.7M; the largest uses were capital spending ($35.8M), taxes on employees’ shares ($15.7M), other investing ($1.9M); besides operations, cash came from shares issued ($3.5M), other financing ($2.6M); the cash balance fell by $7.6M.

Operating cash flow was $19.7M against net income of −$4.1M. The largest differences: stock-based pay +$11.2M, employee-related liabilities +$6.5M, depreciation & amortization +$4.2M.

Its cash conversion cycle was 41 days (receivables 45 + inventory 40 − payables 44).

Free cash flow

Castle Biosciences: free cash flow by quarterCastle Biosciences: free cash flow by quarter$16.8MQ4 2024−$10.8MQ1 2025$11.6MQ2 2025$7.8MQ3 2025$19.7MQ4 2025−$34.6MQ1 2026$6.6MQ2 2026$12.2MQ3 2026
Operating cash flow less capital spending.
Castle Biosciences: operating cash flow against capital spendingCastle Biosciences: operating cash flow against capital spendingOperating cash flowCapital spending$24.4M$7.6MQ4 2024−$6.0M$4.7MQ1 2025$20.8M$9.3MQ2 2025$22.6M$14.8MQ3 2025$26.9M$7.2MQ4 2025−$22.1M$12.5MQ1 2026$15.2M$8.7MQ2 2026$19.7M$7.5MQ3 2026
Latest (Q3 2026): Operating cash flow $19.7M, Capital spending $7.5M.

Capital allocation, year by year

Castle Biosciences: where the cash came from (up) and went (down), by fiscal yearCastle Biosciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsFY2021: Operating cash flow −$19.0MFY2021: Net borrowing −$8KFY2021: Shares issued $4.2MFY2021: Asset sales $10KFY2021: Capital spending −$3.5M$4.2MFY2021FY2022: Operating cash flow −$41.7MFY2022: Shares issued $833KFY2022: Asset sales $195KFY2022: Capital spending −$5.6MFY2022: Acquisitions −$27.0M$1.0MFY2022FY2023: Operating cash flow −$5.6MFY2023: Net borrowing −$142KFY2023: Shares issued $269KFY2023: Asset sales $13KFY2023: Capital spending −$13.6M$282KFY2023FY2024: Operating cash flow $64.9MFY2024: Net borrowing $9.9MFY2024: Shares issued $2.0MFY2024: Asset sales $18KFY2024: Capital spending −$28.3M$76.8MFY2024FY2025: Operating cash flow $64.3MFY2025: Net borrowing −$115KFY2025: Shares issued $2.2MFY2025: Asset sales $45KFY2025: Capital spending −$36.0M$66.6MFY2025
Over these 5 years operating cash flow totalled $62.9M; the largest uses were capital spending ($87.1M) and operating cash flow ($66.3M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$278M
Debt$10.1M
Net cash$268M
Due within a year$4.2M

Castle Biosciences funds itself: free cash flow was $4.0M over the last twelve months, and $278M of cash and investments stands against $10.1M of debt ($4.2M due within a year, 66.6× covered by cash).

Where the cash came from and went

Castle Biosciences: sources (+) and uses (−) of cash, Q3 2026Castle Biosciences: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$19.7MCash drawn (+) / kept (−)−$15.9MCapital spending−$7.5MOther investing$2.8MShares issued$988KTaxes on employees’ shares−$923KOther financing$827KNet borrowing (+) / repaid (−)−$26KAsset & business sales$8K
Castle Biosciences: sources (+) and uses (−) of cash, TTM to Q3 2026Castle Biosciences: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$39.7MCapital spending−$35.8MTaxes on employees’ shares−$15.7MCash drawn (+) / kept (−)$7.6MShares issued$3.5MOther financing$2.6MOther investing−$1.9MNet borrowing (+) / repaid (−)−$101KAsset & business sales$26K

From profit to cash

Castle Biosciences: net income to operating cash flow, Q3 2026Castle Biosciences: net income to operating cash flow, Q3 2026Net income−$4.1MDepreciation & amortization$4.2MStock-based pay$11.2MDeferred taxes$76KOther non-cash$139KReceivables−$3.4MInventory$199KPayables$1.4MAccrued liabilities$1.3MEmployee-related liabilities$6.5MPrepaid and other assets−$1.3MOperating cash flow$19.7M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 202645404441
Q2 202640404733
Q1 202646457417
Q4 202549477819
Q3 202556426236
Q2 202557395641
Q1 202555414254
Q4 202454423957

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$19.7M−$7.5M−$26K$988K−$15.9M$12.2M
Q2 2026$15.2M−$8.7M−$24K$95K$1.6M$6.6M
Q1 2026−$22.1M−$12.5M−$24K$322K$53.0M−$34.6M
Q4 2025$26.9M−$7.2M−$27K$2.1M−$31.2M$19.7M
Q3 2025$22.6M−$14.8M−$31K$77K−$3.3M$7.8M
Q2 2025$20.8M−$9.3M−$31K$19K$7.5M$11.6M
Q1 2025−$6.0M−$4.7M−$26K$18K$30.0M−$10.8M
Q4 2024$24.4M−$7.6M−$26K$373K−$24.8M$16.8M

Castle Biosciences: income statement and cash flow

Castle Biosciences, Q3 2026: revenue $103M (+24% year over year), operating margin -2.7%. The chart follows the revenue to costs, profit and cash.

Castle Biosciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.